Intravitreal triamcinolone acetonide for idiopathic cystoid macular edema

Ingrid U. Scott; Harry W. Flynn; Philip J. Rosenfeld

doi:10.1016/S0002-9394(03)00266-6

Intravitreal triamcinolone acetonide for idiopathic cystoid macular edema

Ingrid U. Scott, Harry W. Flynn, Philip J. Rosenfeld

Ophthalmology

Research output: Contribution to journal › Article › peer-review

47 Scopus citations

Abstract

PURPOSE: To report intravitreal triamcinolone acetonide for idiopathic cystoid macular edema (ICME). DESIGN: Interventional case series. METHODS: Two patients with ICME were treated with intravitreal triamcinolone. RESULTS: In one patient, best-corrected acuity was 20/70 before treatment and 20/30 6 months posttreatment in both eyes. Foveal thickness was 606 μm before and 197 μm posttreatment in the right eye and 542 μm before and 190 μm posttreatment in the left eye. In another patient, best-corrected acuity was 20/200 before treatment and 20/50 5 months posttreatment; foveal thickness was 580 μm before and 208 μm posttreatment. Recurrence of macular edema responded to repeat intravitreal triamcinolone acetonide in both patients. CONCLUSIONS: Intravitreal triamcinolone may be associated with reduced edema and improved vision in patients with ICME; however, these changes may be transient.

Original language	English (US)
Pages (from-to)	737-739
Number of pages	3
Journal	American journal of ophthalmology
Volume	136
Issue number	4
DOIs	https://doi.org/10.1016/S0002-9394(03)00266-6
State	Published - Oct 1 2003

ASJC Scopus subject areas

Ophthalmology

Access to Document

10.1016/S0002-9394(03)00266-6

Fingerprint Dive into the research topics of 'Intravitreal triamcinolone acetonide for idiopathic cystoid macular edema'. Together they form a unique fingerprint.

Cite this

@article{cadd9e5c44d248af9a9bc5e67e7bbdbd,

title = "Intravitreal triamcinolone acetonide for idiopathic cystoid macular edema",

abstract = "PURPOSE: To report intravitreal triamcinolone acetonide for idiopathic cystoid macular edema (ICME). DESIGN: Interventional case series. METHODS: Two patients with ICME were treated with intravitreal triamcinolone. RESULTS: In one patient, best-corrected acuity was 20/70 before treatment and 20/30 6 months posttreatment in both eyes. Foveal thickness was 606 μm before and 197 μm posttreatment in the right eye and 542 μm before and 190 μm posttreatment in the left eye. In another patient, best-corrected acuity was 20/200 before treatment and 20/50 5 months posttreatment; foveal thickness was 580 μm before and 208 μm posttreatment. Recurrence of macular edema responded to repeat intravitreal triamcinolone acetonide in both patients. CONCLUSIONS: Intravitreal triamcinolone may be associated with reduced edema and improved vision in patients with ICME; however, these changes may be transient.",

author = "Scott, {Ingrid U.} and Flynn, {Harry W.} and Rosenfeld, {Philip J.}",

year = "2003",

month = oct,

day = "1",

doi = "10.1016/S0002-9394(03)00266-6",

language = "English (US)",

volume = "136",

pages = "737--739",

journal = "American Journal of Ophthalmology",

issn = "0002-9394",

publisher = "Elsevier USA",

number = "4",

}

TY - JOUR

T1 - Intravitreal triamcinolone acetonide for idiopathic cystoid macular edema

AU - Scott, Ingrid U.

AU - Flynn, Harry W.

AU - Rosenfeld, Philip J.

PY - 2003/10/1

Y1 - 2003/10/1

N2 - PURPOSE: To report intravitreal triamcinolone acetonide for idiopathic cystoid macular edema (ICME). DESIGN: Interventional case series. METHODS: Two patients with ICME were treated with intravitreal triamcinolone. RESULTS: In one patient, best-corrected acuity was 20/70 before treatment and 20/30 6 months posttreatment in both eyes. Foveal thickness was 606 μm before and 197 μm posttreatment in the right eye and 542 μm before and 190 μm posttreatment in the left eye. In another patient, best-corrected acuity was 20/200 before treatment and 20/50 5 months posttreatment; foveal thickness was 580 μm before and 208 μm posttreatment. Recurrence of macular edema responded to repeat intravitreal triamcinolone acetonide in both patients. CONCLUSIONS: Intravitreal triamcinolone may be associated with reduced edema and improved vision in patients with ICME; however, these changes may be transient.

AB - PURPOSE: To report intravitreal triamcinolone acetonide for idiopathic cystoid macular edema (ICME). DESIGN: Interventional case series. METHODS: Two patients with ICME were treated with intravitreal triamcinolone. RESULTS: In one patient, best-corrected acuity was 20/70 before treatment and 20/30 6 months posttreatment in both eyes. Foveal thickness was 606 μm before and 197 μm posttreatment in the right eye and 542 μm before and 190 μm posttreatment in the left eye. In another patient, best-corrected acuity was 20/200 before treatment and 20/50 5 months posttreatment; foveal thickness was 580 μm before and 208 μm posttreatment. Recurrence of macular edema responded to repeat intravitreal triamcinolone acetonide in both patients. CONCLUSIONS: Intravitreal triamcinolone may be associated with reduced edema and improved vision in patients with ICME; however, these changes may be transient.

UR - http://www.scopus.com/inward/record.url?scp=0141793634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141793634&partnerID=8YFLogxK

U2 - 10.1016/S0002-9394(03)00266-6

DO - 10.1016/S0002-9394(03)00266-6

M3 - Article

C2 - 14516818

AN - SCOPUS:0141793634

VL - 136

SP - 737

EP - 739

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 4

ER -